schizophrenia

colorful brain art model
Biotech

Atai's schizophrenia drug fails to improve cognition in phase 2

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study.
James Waldron Jul 28, 2025 7:45am
The Top Line

What were the biggest clinical trial flops of 2024?

Feb 21, 2025 9:00am
Graphic showing arrows missing the bullseye on a target

2024's top 10 clinical trial flops

Feb 18, 2025 3:00am
balloon missed target pop arrows miss failure

Boehringer's schizophrenia drug fails trio of phase 3 trials

Jan 16, 2025 11:58am
Graphic image of a 100 bill falling through a crack opening up

Phase 2 schizophrenia fails will cost AbbVie about $3.5B

Jan 10, 2025 11:06am
schizophrenia mental health brain neurodegenerative

LB Pharma's twist on old Sanofi drug passes schizophrenia test

Jan 8, 2025 7:00am